Alder Biopharmaceuticals Receives $38,000,000 Series D Financing Round

  • Feed Type
  • Date
    4/19/2012
  • Company Name
    Alder Biopharmaceuticals
  • Mailing Address
    11804 North Creek Parkway South Bothell, WA 98011
  • Company Description
    Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics.
  • Website
    http://www.alderbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds of the financing will support clinical development of ALD518 and ALD403. ALD518, a monoclonal antibody to the pro-inflammatory cytokine IL-6, is currently being investigated in ongoing Phase 2 clinical studies in cancer related indications, which were retained by the company in its partnership with Bristol-Myers Squibb in 2009.
  • M&A Terms
  • Venture Investor
    Novo A/S
  • Venture Investor
    Sevin Rosen Funds
  • Venture Investor
    Ventures West
  • Venture Investor
    WRF Capital
  • Venture Investor
    H.I.G. Capital
  • Venture Investor
    Delphi Ventures
  • Venture Investor
    TPG Biotech

By posting a comment, you agree to our terms and conditions.